We are live on ! Find out more
GEVA

SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA

Delisted

GEVA was delisted on the 22nd of June, 2015.

Back to rankings

0 hedge funds and large institutions have $0 invested in SYNAGEVA BIOPHARMA CORP COM STK (DE) in 2015 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 130 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 130 → 0 (-130)

100% less funds holding in top 10

Funds holding in top 10: 3 → 0 (-3)

100% less capital invested

Capital invested by funds: $3.89B → $0 (-$3.89B)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 130

Holders
–
Holders Change
-130
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
130
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
BBA
Baker Bros. Advisors
New York
-$1.14B
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$541M
3
Capital Research Global Investors
Capital Research Global Investors
California
-$442M
4
CWAM
Columbia Wanger Asset Management
Illinois
-$317M
5
Vanguard Group
Vanguard Group
Pennsylvania
-$152M
Name Holding Trade Value Shares
Change 		Change in
Stake
BBA
1
Baker Bros. Advisors
New York
– -$1.14B -11,660,432 Closed
Fidelity Investments
2
Fidelity Investments
Massachusetts
– -$541M -5,543,741 Closed
Capital Research Global Investors
3
Capital Research Global Investors
California
– -$442M -4,527,358 Closed
CWAM
4
Columbia Wanger Asset Management
Illinois
– -$317M -3,245,542 Closed
Vanguard Group
5
Vanguard Group
Pennsylvania
– -$152M -1,554,979 Closed
Capital World Investors
6
Capital World Investors
California
– -$123M -1,262,798 Closed
BFA
7
BlackRock Fund Advisors
California
– -$103M -1,058,768 Closed
T. Rowe Price Associates
8
T. Rowe Price Associates
Maryland
– -$101M -1,037,935 Closed
BB
9
BB Biotech
Switzerland
– -$100M -1,025,476 Closed
Wells Fargo
10
Wells Fargo
California
– -$77.8M -797,807 Closed
BIT
11
BlackRock Institutional Trust
California
– -$59.6M -610,716 Closed
Wellington Management Group
12
Wellington Management Group
Massachusetts
– -$57.9M -593,823 Closed
State Street
13
State Street
Massachusetts
– -$56.9M -583,000 Closed
JHIU
14
Janus Henderson Investors US
Colorado
– -$55.8M -572,037 Closed
AllianceBernstein
15
AllianceBernstein
Tennessee
– -$48M -492,190 Closed
Lord, Abbett & Co
16
Lord, Abbett & Co
New Jersey
– -$37.9M -388,980 Closed
EAM
17
Eagle Asset Management
Florida
– -$36.3M -371,816 Closed
SAM
18
Sectoral Asset Management
Quebec, Canada
– -$35.7M -365,684 Closed
Invesco
19
Invesco
Georgia
– -$35.5M -364,160 Closed
JP Morgan Chase
20
JP Morgan Chase
New York
– -$27.9M -286,447 Closed
Northern Trust
21
Northern Trust
Illinois
– -$26M -266,963 Closed
Norges Bank
22
Norges Bank
Norway
– -$19.7M -201,582 Closed
TCM
23
Tekla Capital Management
Massachusetts
– -$19.4M -198,689 Closed
BA
24
BlackRock Advisors
Delaware
– -$18.2M -187,036 Closed
Axa
25
Axa
France
– -$17.2M -176,224 Closed
1
2 3 4 5

GEVA Hedge Fund Activity: Q2 2015 in Review

0 of the 3,713 institutional investors tracked by Wall St. Rank reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) for Q2 2015, worth a combined $0 — down 100% from $3.89B a quarter earlier.

Sellers outnumbered buyers: 130 funds closed out of GEVA and 0 opened new positions — a net loss of 130 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $1.14B sold.

  • 0 institutional investors held SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) as of Q2 2015, down from 130 in Q1 2015.
  • Funds reported $0 of SYNAGEVA BIOPHARMA CORP COM STK (DE) stock for Q2 2015, down 100% quarter-over-quarter.
  • 0 funds opened new SYNAGEVA BIOPHARMA CORP COM STK (DE) positions in Q2 2015 and 130 closed out, a net change of -130 holders.
  • The largest SYNAGEVA BIOPHARMA CORP COM STK (DE) seller in Q2 2015 was Baker Bros. Advisors, an estimated $1.14B sold.

Based on aggregated 13F filings for Q2 2015.